Abstract: To investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on the risk of acute pancreatitis in patients with type 2 diabetes.
INTRODUCTION

D
ipeptidyl peptidase-4 (DPP-4) inhibitors inhibit glucagon secretion by increasing the endogenous blood level of active incretin, thereby prolonging incretin action and stimulating insulin secretion in a glucose-dependent manner. 1 Overall, DPP-4 inhibitors have modest effects in lowering the plasma glucose level and reducing the risk of hypoglycemia compared with other antidiabetic agents, and they have no substantial effect on body weight. 2, 3 However, the possible association of DPP-4 inhibitor use with pancreatitis has raised concern; events of acute pancreatitis, including fatal hemorrhagic or necrotizing pancreatitis, have been reported in the postmarketing period for these drugs. [4] [5] [6] Previous observational studies of this association, based on clinical databases from various countries, have yielded inconsistent results due to differences in medications, study populations and designs, as well as inadequate duration of follow-up and adjustment for confounders such as comorbidity and disease severity. [7] [8] [9] Some studies have linked these drugs to an increased risk of acute pancreatitis, whereas others have shown that this risk is not increased in DPP-4 inhibitor users compared with nonusers. The association between DPP-4 inhibitor use and acute pancreatitis thus remains inconclusive.
Given the increasing number of patients receiving prescriptions for DPP-4 inhibitors and concerns regarding the significant risks of morbidity and mortality caused by acute pancreatitis in these patients, we conducted a large populationbased cohort study to determine whether the use of DPP-4 inhibitors is associated with an increased risk of acute pancreatitis in patients with newly diagnosed type 2 diabetes in Taiwan.
METHODS
The ethics committee for clinical research of Taichung Veterans General Hospital approved this study. Data were scrambled using a double-scrambling protocol to protect individuals' privacy. As data were anonymized before analysis, informed consent was not required. We selected a cohort of patients with newly diagnosed type 2 diabetes between January 1, 2008 and December 31, 2009 from the LHDB, excluding patients with evidence of acute pancreatitis before diabetes onset and those aged <18 years. The study cohort was followed from the index date to the onset of acute pancreatitis (ICD-9-CM code 577.0) or December 31, 2011.
Study Population
Variable Definitions
Patients with at least 3 ambulatory claims with an ICD-9-CM code of 250.x2 during the inclusion period were classified as having type 2 diabetes. The severity of diabetes was defined using the Diabetes Complications Severity Index (DCSI; 0, 1, or !2).
14 -16 Acute pancreatitis was defined by the registry of a primary or secondary ICD-9-CM code of 577.0 during hospitalization. Baseline comorbidities were defined according to corresponding ICD-9-CM codes registered in 3 outpatient claims before the acute pancreatitis index date: hypertriglyceridemia (ICD-9-CM code 272.1), cholelithiasis (ICD-9-CM code 574), alcohol use (ICD-9-CM code 292, 303), biliary cancer (ICD-9-CM code 156), pancreatic cancer (ICD-9-CM code 157), and hepatocellular carcinoma (ICD-9-CM code 155).
Medication Use
As the marketing of DPP-4 inhibitors was authorized recently in Taiwan (2009, 2011, 2011 , and 2012 for sitagliptin, saxagliptin, vildagliptin, and linagliptin, respectively), linagliptin was not included in our study because it was not available during the study period. We identified all patients who received new prescriptions for DPP-4 inhibitors, including sitagliptin, saxagliptin, and vildagliptin, as monotherapy or in combination with other drugs, during the study period.
Statistical Analysis
We used descriptive statistics to summarize the characteristics of DPP-4 inhibitor users and nonusers. The 2 groups were compared using independent Student t tests for parametric continuous data and Chi-squared tests for categorical data. Subgroup analyses stratified by age and sex were conducted. A Cox proportional-hazards regression model with time-varying covariates was used to evaluate the association between DPP-4 inhibitor use and acute pancreatitis, with calculation of adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). The models were adjusted for alcohol use, hypertriglyceridemia, cholelithiasis, neoplasm, and DCSI score. Survival time was calculated from the date of diabetes onset to the date of acute pancreatitis onset or the end of the study period (December 31, 2011). Two-tailed P values <0.05 were considered to be significant. Data analyses were conducted using SAS software (version 9.3 for Windows; SAS Institute, Inc., Cary, NC). Table 2 ). Significant interaction effects were observed between sex and age (HR 0.80, 95% CI: 0.64-0.99) and between age and DCSI score (HR 0.83, 95% CI: 0.71-0.97).
RESULTS
Stratified subgroup analyses revealed significant differences in the risk of acute pancreatitis according to DPP-4 inhibitor use (Table 3) . Female, but not male, DPP-4 inhibitor users had a significant risk of acute pancreatitis development. Among women, analyses controlling for age, comorbidities, and DCSI score showed that the risk of acute pancreatitis was significantly higher in DPP-4 inhibitor users than in nonusers (HR 2.27, 95% CI: 1.30-3.97). In age-stratified analyses, the risk of acute pancreatitis was significant in DPP-4 inhibitor users aged !65 years, but not in those aged <65 years. Among patients aged >65 years, users had a significantly higher risk of acute pancreatitis than did nonusers (HR 2.39, 95% CI: 1.11-5.15).
DISCUSSION
The results of our cohort study revealed significant interactions of age with sex and DCSI score in the estimation of acute pancreatitis risk among DPP-4 inhibitor users. We found increased risks in subgroups after stratification by sex and age.
Among women and patients aged >65 years, the risk of acute pancreatitis development was significantly higher in DPP-4 inhibitor users than in nonusers.
Gallstone disease, alcohol consumption, and cigarette smoking have been found to be important risk factors for acute pancreatitis. [17] [18] [19] In Taiwan, the overall prevalence of gallstone disease is 5.0% (4.6% in men, 5.4% in women), with no 20 ; alcohol consumption and cigarette smoking are more prevalent in men than in women. 21, 22 Taiwan has particularly high male smoking prevalence and much lower female prevalence. 22 Smoking and alcohol consumption patterns also differ between younger and older populations. 22 Differences in the risk of acute pancreatitis may be related to differences between male and female characteristics, including body composition, fat distribution, sex hormones, physical activity, and lifestyle. 23 Obesity has been associated with the severity of this disease, 24 and the age-adjusted prevalence of obesity was higher in men than in women of Taiwan. 25 In this study, the identification of significant interaction effects prompted stratified analyses, which revealed age-and sexrelated differences in the risk of acute pancreatitis that were not apparent in the analysis of the total population. In Table 1 , the crude ratio of acute pancreatitis between the 2 groups were compared using Chi-squared tests, which is quite significant (P ¼ 0.0003). In Table 2 , a Cox proportional-hazards regression model with time-varying covariates was used to evaluate the association between DPP-4 inhibitor use and acute pancreatitis after controlling for age, sex, comorbidities, and DCSI score, the risk of acute pancreatitis was not significantly higher among DPP-4 inhibitor users than among nonusers (HR 1.32, 95% CI: 0.88-1.99). Besides, in Table 2 , significant interaction effects were observed between sex and age (HR 0.80, 95% CI: 0.64-0.99) and between age and DCSI score (HR 0.83, 95% CI: 0.71-0.97). It means that the effect of age on acute pancreatitis development is different among men and women, and among different DCSI score. In such condition, it is necessary to perform stratified analysis to separate the data and run multiple models (Table 3) . Further studies are needed to confirm our results and explore underlying mechanisms.
The results of this study are consistent with those of a meta-analysis of randomized controlled trials 26 and some observational studies examining the effects of DPP-4 inhibitors on acute pancreatitis. 8, 9, 27, 28 In a retrospective cohort study utilizing the Medco National Integrated Database in United States, Garg et al 27 demonstrated an increased incidence of acute pancreatitis in diabetic compared with nondiabetic patients, but they found no association between the use of exenatide or sitagliptin and acute pancreatitis. Using data from the UK's Clinical Practice Research Datalink, Faillie et al 8 found that the use of incretin-based drugs was not associated with an increased risk of acute pancreatitis compared with the use of sulfonylureas. Chou et al 9 conducted a population-based nested casecontrol study using Taiwan's NHIRD. The results showed that the risks of acute pancreatitis among current and past DPP-4 inhibitor users were not significantly higher than that among nonusers. In a nationwide population-based case-control study utilizing medical databases in Denmark, Thomsen et al 28 revealed no significantly increased risk of acute pancreatitis in users of incretin-based drugs, including glucagon-like peptide-1 receptor agonists and DPP-4 inhibitors. However, our results contrast with those of 2 case-control studies. 7, 29 In a population-based case-control study using a large US administrative database, Singh et al 7 found that treatment with sitagliptin and exenatide was associated with increased odds of hospitalization for acute pancreatitis in patients aged 18 to 65. Soranna et al 29 showed that incretin-based drug use significantly increased the risk of acute pancreatitis development in a nested-case-control study based on a healthcare database with a cohort of 166,591 patients aged !40 years from the Lombardy region of Italy. Inconsistent results of these observational studies may due to limited statistical power, inadequate following time and confounding factors, such as comorbidities and diabetes disease severity.
Our study has several strengths. We used the LHDB, which enabled examination of a large sample representing the entire diabetic population of Taiwan. To avoid bias in our assessment of the risk of acute pancreatitis due to the duration of diabetes, which may increase this risk, 30, 31 we selected patients with newly diagnosed diabetes. We adjusted for a large number of confounders for which data were available, including alcohol use, hypertriglyceridemia, cholelithiasis, neoplasm, and DCSI score. We also investigated the elderly population, which has rarely been included in previous studies. Our survival analyses included time-dependent variables, which improves the accuracy of results. 32 We also accounted for interactions of age with sex and DCSI score in examining associations between DPP-4 inhibitor use and acute pancreatitis development by performing stratified subgroup analyses.
However, our findings must be interpreted with caution, given the inherent limitations of the retrospective observational design and reliance on insurance and pharmacy claims data, which may be incomplete and incorporate unknown confounders. The claims data lacked some patient information, such as body mass index, family history, smoking habit, blood pressure, lipid profile, and hemoglobin A1c level. Misclassification of pancreatitis may have occurred because we did not have access to clinical records, radiological images, or diagnostic markers, such as serum amylase and lipase levels. Drug exposure may also have been misclassified because this information was derived from pharmacy claims, and we cannot guarantee that patients ingested the medication. Furthermore, immortal time bias may affect the results of cohort studies in favor of the treatment group. 33 As the marketing of DPP-4 inhibitors was authorized recently in Taiwan (2009, 2011, 2011 , and 2012 for sitagliptin, saxagliptin, vildagliptin, and linagliptin, respectively), the LHDB contained data for a limited follow-up period (about 2 years). Linagliptin was not included in our study because it was not available during the study period. The longer-term safety of DPP-4 inhibitors should thus be investigated further. Finally, we did not impute for missing data in our analyses.
CONCLUSIONS
This population-based cohort study revealed significant interaction effects between sex and age, and age and DCSI score, on the association between DPP-4 inhibitor use and acute pancreatitis among patients with new-onset type 2 diabetes. Subgroup analyses showed that female DPP-4 inhibitor users and those aged >65 years had significantly increased risks of acute pancreatitis development. Our findings provide both reassurance and reason for caution to physicians and high-risk patients using these drugs. Further large well-conducted observational studies are needed to confirm our results.
